Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
573.6 USD | +0.13% | -0.23% | +8.07% |
May. 08 | Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip | RE |
May. 02 | Thermo Fisher Scientific Insider Sold Shares Worth $5,737,356, According to a Recent SEC Filing | MT |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.2 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.07% | 219B | B | ||
+7.87% | 185B | B- | ||
+12.75% | 135B | B- | ||
-1.37% | 62.21B | A- | ||
+4.88% | 51.01B | B+ | ||
+11.59% | 51.28B | B+ | ||
+2.71% | 41.85B | A | ||
+4.90% | 37.02B | - | ||
+23.75% | 31.27B | B+ | ||
+16.47% | 23.66B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TMO Stock
- Ratings Thermo Fisher Scientific